CTI BioPharma Investor
CTI BioPharma is a company that focuses on developing and selling cancer treatment products. One of its main products in development is Pixantrone, which is currently in phase III trials and is intended for non-Hodgkin's lymphoma.
Founded Date:
1991
Investor Type:
For Profit
Estimated Revenue:
$1M to $10M
Employee Number:
11-50
Industry:
Biotechnology
Headquarters:
Seattle, Washington, United States
Funding Status:
IPO